Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Bristol-Myers Squibb
Fudan University
Mabwell (Shanghai) Bioscience Co., Ltd.
AstraZeneca
Duke University
Akeso
QuantumLeap Healthcare Collaborative
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Novartis
PMV Pharmaceuticals, Inc
Mayo Clinic
Dartmouth-Hitchcock Medical Center
Novartis
NiKang Therapeutics, Inc.
University of Washington
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Wake Forest University Health Sciences
BeOne Medicines
UNC Lineberger Comprehensive Cancer Center
Aktis Oncology, Inc.
Genmab
Exelixis
Tubulis GmbH
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Eli Lilly and Company
Affiliated Hospital of Nantong University
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Sumitomo Pharma America, Inc.
OncoTherapy Science, Inc.
Bristol-Myers Squibb
Shandong Cancer Hospital and Institute
Accent Therapeutics
Seagen Inc.
Japanese Foundation for Cancer Research
ProteinQure Inc.
University of Alabama at Birmingham
NEC Bio B.V
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
The Methodist Hospital Research Institute